As a conclusion, the research clarified a positive role of Ruscogenin against SS and demonstrated that Ruscogenin ameliorated SS by inhibiting NLRP3 inflammasome activation through experiments in vivo and in vitro, providing an innovative and potential drug for SS treatment. Here, NLRP3 is linked to synovial sarcoma.